Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) EBT Margin (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed EBT Margin for 9 consecutive years, with 2240.9% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin changed N/A year-over-year to 2240.9%; the TTM value through Mar 2026 reached 470814.71%, changed N/A, while the annual FY2025 figure was 1401.16%, N/A changed from the prior year.
  • EBT Margin hit 2240.9% in Q1 2026 for Crescent Biopharma, down from 2030.75% in the prior quarter.
  • Across five years, EBT Margin topped out at 2030.75% in Q2 2025 and bottomed at 17690.09% in Q2 2022.
  • Average EBT Margin over 3 years is 5966.75%, with a median of 2240.9% recorded in 2026.
  • On a YoY basis, EBT Margin climbed as much as 1012263456bps in 2022 and fell as far as 1012263456bps in 2022.
  • Crescent Biopharma's EBT Margin stood at 17690.09% in 2022, then surged by 111bps to 2030.75% in 2025, then crashed by -210bps to 2240.9% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 2240.9%, 2030.75%, and 17690.09% for Q1 2026, Q2 2025, and Q2 2022 respectively.